Virobay Facts

2014 – Virobay completes $8 million Series B preferred stock financing more

2014 – Virobay announces the appointment of James Welch as Chief Financial Officer more

2014 – Virobay appoints Thomas J. Dietz, Ph.D. to the Virobay Board of Directors more

2013 – Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain more

2013 – Virobay and LEO Pharma initiate a Phase 1 Trial of VBY-891, a compound intended for oral treatment of psoriasis more

2012 – Virobay's Cathepsin S selected as one of the Top 10 Anti-Inflammatory/Autoimmune Projects to Watch more

2012 – LEO Pharma A/S has entered into a multi-million dollar collaboration with Virobay Inc. to develop an oral treatment for psoriasis more

2010 – Virobay closes Series B financing


Welcome to Virobay, leaders in protease inhibitor design.

At Virobay we are developing protease inhibitors for the treatment of autoimmune diseases, neuropathic pain, liver diseases and cancer.

Our virtual model of drug discovery and development combines extensive in-house expertise with the resources of contract research and manufacturing facilities worldwide for cost effective and efficient development.

Our Pipeline

Virobay Pipeline Table
Phase 0
(Clinical Candidate)
Phase 1
Phase 2
Psoriasis - LEO Pharma     X  
Pain     X  
Autoimmunity     X  
Fibrosis/NASH     X  
Fibrosis/PBC   X    
Autoimmunity   X    
Multiple Candidates
Cancer, Alzheimer's X